HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus radiation trial for head and neck cancer halted early
Disease control TerminatedThis study tested whether adding radiation to the immunotherapy drug pembrolizumab could help control metastatic head and neck cancer that had already been treated once. It was designed for adults with at least two tumors, one of which would receive radiation. The trial was termi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated May 17, 2026 03:27 UTC
-
Experimental cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or delay cancer growth. The trial was ter…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated e…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo targets tough cancers in early trial
Disease control TerminatedThis early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The st…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Head and neck cancer drug combo study halted early
Disease control TerminatedThis study tested a new drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The study was terminated early, so results are l…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Experimental combo therapy trial halted early
Disease control TerminatedThis early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated, so result…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Tiny trial tests smarter chemo delivery in head and neck cancer
Knowledge-focused TerminatedThis very early study aimed to see how a new version of the chemotherapy drug paclitaxel (called FID-007) affects immune cells around head and neck tumors. The drug was designed to reach deeper into tumors while causing fewer side effects. Only one person took part before the stu…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated May 17, 2026 03:32 UTC